ALK and non-small cell lung carcinoma: For NSCLC adenocarcinoma patients, biomolecular profile analysis was carried out and 26 (30.2% of total patients, 38.2% among NSCLC histology) were “mutated” (i.e., carriers of a driver mutation): 21 (30.9% of 68) had a genetic alteration of EGFR and among them, 5 carried the KRAS g12C pathogenic variant, while no patients had alterations in ALK and ROS1.